A Retrospective Cohort Study of Mavacamten Patient Support Program in Canada
- Registration Number
- NCT06549608
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This real-world study will describe the demographic and clinical characteristics and mavacamten treatment of adult patients with obstructive hypertrophic cardiomyopathy who participated in the Bristol-Myers Squibb (BMS)-sponsored CAMZYOS Patient Support Program in Canada.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 685
Inclusion Criteria
- Participants ≥18 years of age.
- Participants who have initiated mavacamten as part of routine clinical care, through the BMS-sponsored CAMZYOS Patient Support Program for the treatment of symptomatic obstructive hypertrophic cardiomyopathy.
- Participants who consented to the use of their de-identified data, generated from information collected in the course of the program.
Exclusion Criteria
• There are no exclusion criteria.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Adults participants treated with mavacamten Mavacamten Participants with symptomatic obstructive hypertrophic cardiomyopathy (NYHA functional class II-III) who receive mavacamten as part of routine clinical care.
- Primary Outcome Measures
Name Time Method Participant clinical characteristics Baseline Participant demographics Baseline
- Secondary Outcome Measures
Name Time Method Dose regimen of mavacamten treatment Every 3-months up to 14 months Titration patterns of mavacamten treatment Up to 14 months Mavacamten treatment duration Up to 14 months
Trial Locations
- Locations (1)
St. Paul's Hospital
🇨🇦Vancouver, British Columbia, Canada